There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?

California health officials report rising influenza cases and hospitalizations and confirmed a second pediatric death in the state this season (17 pediatric deaths nationwide), with CDPH detecting H3N2 subclade K—called a “super flu”—on Jan. 13 and the CDC warning elevated flu activity will likely continue for several weeks. Test positivity in Southern California is currently moderate (and lower than last year at the same time), COVID-19 activity is very low, and RSV positivity is moderate; CDPH recommends vaccination. For investors, this is a regional public-health development that could modestly raise short-term healthcare utilization and workforce absenteeism risk but is unlikely to drive broad market moves.

Analysis

Market structure: A localized SoCal uptick in influenza/RSV (moderate test positivity) tilts near-term demand to diagnostics, outpatient Rx, pharmacies and hospital ERs. Winners: rapid-test and immunization manufacturers (e.g., ABT, QDEL, TMO, SNY, GSK, PFE) and hospital operators (HCA, THC) for a 4–12 week window; losers: discretionary travel/leisure (JETS, AAL) and hourly-labor-intensive service firms if absenteeism rises >5% week-over-week.

Risk assessment: Tail risks include a more virulent H3N2 surge or a simultaneous COVID/RSV wave that materially increases hospitalizations beyond capacity (stress test: pediatric deaths rising from 17 to >50 nationally in 4–8 weeks), which would broaden impacts to insurers (UNH, CVS) and supply chains. Immediate effects (days–2 weeks) are volume shocks to EDs and test demand; short-term (1–3 months) are revenue bumps for diagnostics/vaccines and claims pressure for insurers; long-term (3–12 months) depend on vaccine uptake and potential regulatory pricing scrutiny.

Trade implications: Favor short-duration, sector-targeted exposures: long diagnostics/vaccine names via call spreads to capture IV yet limit downside; pair long hospitals vs short travel/leisure; small shorts in regional leisure names where booking elasticity is highest. Monitor IV and sell premium on travel names if implied vol > historical vol by 30% and scale protective hedges if RSV/COVID co-positivity rises >10% of tests.

Contrarian angles: Consensus underestimates operational pain for labor-dependent services—absenteeism shock could compress small-cap margins more than headline case counts imply; conversely, the market may overpay for “safe” vaccine names where seasonal demand is already priced. Historical parallel: 2017–18 H3N2 spikes produced 6–12% outperformance in diagnostics vs S&P over 3 months; if SoCal metrics don’t spill nationally within 4 weeks, diagnostic longs should be trimmed.

Key Decisions for Investors

• Establish a 2–3% portfolio allocation via 60–90 day call-spread on Abbott (ABT) and QuidelOrtho (QDEL) to capture test-demand upside; target 20–40% upside on spreads and cut if SoCal test positivity falls >20% week-over-week.
• Take a 1.5–2% long position in HCA Healthcare (HCA) and Tenet (THC) (equal weight) and pair with a 1% short exposure to the airline ETF JETS (ratio 1:1) to play higher ER volumes vs travel softness over next 4–12 weeks; trim longs if hospital census growth stalls for two consecutive weeks.
• Buy 1–2% notional 45–90 day put protection on JETS or top leisure small-caps (AAL, DAL) if implied volatility is <30% and initiate outright short (0.5–1%) if IV >50% and bookings data show >10% cancellation uplift month-over-month.
• Monitor CDC weekly indicators: scale diagnostic/vaccine longs by +50% if pediatric deaths >30 nationally or combined respiratory test positivity in SoCal rises >25% week-over-week; reduce exposure by 50% if the above metrics do not materialize within 4 weeks.